Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.33 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22085540 | 0.89 | CA14 (0.31) | HDAC6HDAC1HDAC2KCNQ4KCNQ5 | |
| SCHEMBL1696194 | 0.87 | HDAC6 (0.35) | HDAC6HDAC1HDAC2KCNQ4KCNQ5 | |
| SCHEMBL1207293 | 0.83 | CA14 (0.39) | HDAC6HDAC1HDAC2KCNQ4KCNQ5 | |
| SCHEMBL1743767 | 0.82 | HDAC6 (0.35) | HDAC6HDAC1HDAC2KCNQ4KCNQ5 | |
| SCHEMBL10339672 | 0.81 | HDAC6 (0.37) | HDAC6HDAC1HDAC2CA14CTSD | |
| SCHEMBL29850241 | 0.81 | KCNQ4 (0.34) | KCNQ4KCNQ5CA14 | |
| SCHEMBL15285654 | 0.81 | — | — | |
| SCHEMBL7073506 | 0.80 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL30897721 | 0.80 | HDAC6 (0.34) | HDAC6HDAC1HDAC2KCNQ4KCNQ5 | |
| SCHEMBL15286314 | 0.79 | HDAC6 (0.32) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133217-A1 | COMPOUNDS | FLINDR THERAPEUTICS B. V. (NL) | 2025-06-26 | — | — | WO | disclosed |
| US-20250188089-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4543859-A1 | 3-(SULPHONYL OR SULFONIMIDOYL)PROP-2-EN-1-YL]-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES | Flindr Therapeutics B.V. (NL) | 2025-04-30 | — | — | EP | disclosed |
| US-12240828-B2 | Heteroaromatic compounds as vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-03-04 | — | — | US | disclosed |
| EP-3890828-B1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-02-19 | — | — | EP | disclosed |
| US-12187734-B2 | Substituted pyridotriazine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4196479-B9 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240300966-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-09-12 | — | — | US | disclosed |
| EP-4321217-A2 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11897892-B2 | Substituted pyridotriazine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11613546-B2 | Substituted pyridotriazine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| WO-2023019166-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023019166-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20220267343-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-08-25 | — | — | US | disclosed |
| WO-2022159387-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| WO-2020114947-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-11 | — | — | WO | disclosed |
| US-20170174695-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| WO-2004074336-A1 | NOVEL CATIONIC COPOLYMERS, USE THEREOF FOR THE VECTORISATION OF BIOMOLECULES AND SYNTHETIC INTERMEDIATES FOR THE SAME | HALISOL (FR) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240828-B2 | Heteroaromatic compounds as vanin inhibitors | VHL, FANCI, PAH | HDAC6 1437/4885HDAC1 1745/4885HDAC2 925/4885 |
| US-11897892-B2 | Substituted pyridotriazine compounds and uses thereof | TPMT, TYMP, DPYD | HDAC6 2449/4885HDAC1 1956/4885HDAC2 2542/4885 |
| US-20170174695-A1 | NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS | TP53, MDM2, FOXM1 | HDAC6 636/4885HDAC1 394/4885HDAC2 594/4885 |
| US-11613546-B2 | Substituted pyridotriazine compounds and uses thereof | TPMT, TYMP, DPYD | HDAC6 2449/4885HDAC1 1956/4885HDAC2 2542/4885 |
| US-12187734-B2 | Substituted pyridotriazine compounds and uses thereof | TPMT, TYMP, DPYD | HDAC6 2449/4885HDAC1 1956/4885HDAC2 2542/4885 |
| US-20250188089-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | TPMT, TYMP, DPYD | HDAC6 2449/4885HDAC1 1956/4885HDAC2 2542/4885 |
| US-20220048889-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | HDAC6 1437/4885HDAC1 1745/4885HDAC2 925/4885 |
| US-20220267343-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | TPMT, TYMP, DPYD | HDAC6 2449/4885HDAC1 1956/4885HDAC2 2542/4885 |
| US-20240300966-A1 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | TPMT, TYMP, DPYD | HDAC6 2449/4885HDAC1 1956/4885HDAC2 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.